EUCTR2017-000614-39-NO进行中（未招募）1 期
Prevention of graft-versus-host disease in patients treated with allogeneic stem cell transplantation: Possible role of extracorporeal photophoresis
OSLO UNIVERSITY HOSPITAL HF0 个研究点目标入组 156 人开始时间: 2017年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 156
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients > 18 yrs diagnosed with acute or chronic leukemia, chronic myeloproliferative disease, myelodysplastic syndromes and lymphomas according to WHO-criteria and that are suitable fora first-time allogeneic stem cell transplatation according to our national guidelines.
- •-Provide written consent to participate
- •-Understand Norwegian or English
- •-No previous history of malignant disease
- •-No contraindication to ECP-treatment or undergone previous ECP treatment
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 120
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 40
排除标准
- •In addition to those regarding eligibility for transplantation itself:
- •-Unwilling to provide written consent to participate
- •-Unable to cooperate as judged by the responsible physician
- •-ECOG status > 2 at time of inclusion
- •-Using anti-inflammatory or cytotoxic drugs other than those that are part of the treatment of the current hematological malignancy
- •-Known allergy to psoralen or citrate products
研究者
相似试验
招募中
2 期
Single agent GVHD prophylaxis with PTCY for SCT: a phase II studyeukemia/lymphomaHematologic malignancyJPRN-jRCTs031180399Sakaguchi Hirotoshi30
招募中
不适用
Single agent graft-versus-host disease prophylaxis with post-transplant cyclophosphamide for stem cell transplantation: a phase II study (SAP-P2)Acute leukemiaJPRN-UMIN000021375ational Center for Child Health and Development30
进行中（未招募）
1 期
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-thymocyte-globulin (ATG) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study - NDAcute myeloid leukemia in first or subsequent complete remissionMedDRA version: 9.1Level: HLTClassification code 10024291Term: Leukaemias acute myeloidEUCTR2005-005719-83-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI160
进行中（未招募）
不适用
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-Tlymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantantioAcute lymphoblastic and myeloid leukemiaMedDRA version: 14.1Level: LLTClassification code 10000842Term: Acute lymphatic leukaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2005-005719-83-ESniversitary Hospital Hamburg160
进行中（未招募）
不适用
Prophylaxis of chronic graft-versus-host disease (cGvHD) with or without anti-T-lymphocyte-globulin (ATG Fresenius) prior allogeneic peripheral stem cell transplantation from HLA-identical siblings after myeloablative conditioning in patients with acute leukemia: a randomized phase III-study - not availableacute lymphoblastic and myeloid leukemiaMedDRA version: 8.1Level: LLTClassification code 10024330Term: Leukemia acuteEUCTR2005-005719-83-DEniversity Hospital Hamburg-Eppendorf160